Physician profile
Mark Taylor
NPI 1821088857
$5,423.00
in general payments reported to CMS, 2019-2025
25 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $104 · 2021: $482 · 2022: $631 · 2023: $1,361 · 2024: $1,305 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.55 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,013.02 | 2022-2025 | Jot Dx, Amplatzer Amulet, Mitraclip |
| Abiomed | $568.19 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $514.42 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $498.18 | 2019-2025 | |
| Pfizer INC. | $247.60 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $246.56 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $179.65 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $162.55 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.42 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $134.05 | 2019-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $110.77 | 2023-2024 | Inpefa |
| Medtronic, INC. | $86.03 | 2021-2022 | |
| Novo Nordisk INC | $84.42 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $69.29 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $68.77 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60.14 | 2024-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $45.04 | 2019-2023 | Opsumit, Uptravi |
| Bard Peripheral Vascular, INC. | $41.98 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $39.22 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $26.73 | 2021 | |
| Lantheus Medical Imaging, INC. | $22.87 | 2023 | Definity |
| Teleflex LLC | $19.66 | 2022 | |
| Amgen INC. | $15.43 | 2025 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $14.81 | 2022 | |
| Cardiovascular Systems INC. | $5.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.